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raveler’s rickettsioses and domestic rickettsioses in Japan in
011
. Ando ∗, Y. Ogasawara
National Institute of Infectious Diseases, Tokyo, Japan
Background: Various rickettsioses distribute worldwide. Scrub
yphus and Japanese spotted fever are known in Japan. Each rick-
ttsiosis is reported about 400 cases and over 100 cases every year
nd has seasonal and geographical characteristics. In contrast, trav-
ler’s rickettsioses are febris acute diseases to need attention for
ll season and nationwide. In 2011, we experienced a laboratory
iagnosis of various rickettsioses.
Methods: In many time, untypical cases and imported cases are
equested to perform laboratory diagnosis for our laboratory. We
erformedseveral PCR tests, targeteddifferent reckettsial sequence
egions, and measure antibody titer. We detected a rickettsial spe-
iﬁc gene from acute phase samples (eschars, skin biopsy of rash
ndwhole blood) and conﬁrmedantibody titers elevationbypaired
era.
Results: ThreeAfrican tick bite fever caseswere diagnosed (case
traveled to Swaziland and case 2 to South Africa in January, and
ase 7 traveled to Zimbabwe and Botswana in December). Case
was forgrin traveler from South Africa, and diagnosed as Bou-
onnese fever. Case 5 was Scrub typhus who traveled to Malaysia
n March. Case 6 was murine typhus, who stayed in Thailand and
howed acute respiratory disorder syndrome in April. On the other
and, case 4 was suggested as the new spotted fever group Rick-
ttsia by results of genetic sequence analysis of PCR products and
howed antibody elevation against Rickettsia conorii.
Conclusion: Antigenic cross-reactivity are high among spot-
ed fever rickettsia group, there is a limit for differentiation of
nfected Rickettsia species by serologic diagnosis. In addition,mem-
ers of spotted fever group Rickettsia have increased until now.
potted fever rickettsioses show variety in clinical symptom, and
ave various outbreak situation anddistribution. Therefore, history
nd episodes of the patients before onset are extremely impor-
ant. In this presentation,we summarize traveler’s rickettsioses and
omestic rickettsioses in 2011 in Japan.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.398
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linical study on efﬁcacy and safety of piperamisinin
dihydroartemisinin-piperaquine) in uncomplicated falci-
arum malaria
.M. Hlaing ∗, K.Z. Oo, K.P. PyarDirectorate of Medical Services, Nay Pyi Taw, Myanmar
Background: Dihydroartemisinin and piperaquine phosphate
o-formulated tablets manufactured from Pharmaceutical Com-fectious Diseases 16S (2012) e317–e473 e337
panies of Republic of China namely Artekin and Artepip had
been studied in Clinical Research Unit (Malaria) No. (1) DSGH
(1000-Beds) Mingalardon in 2006-2008 for the treatment of
uncomplicated falciparum malaria and it was found to be safe
and effective. Piperamisinin, a combined tablet, containing 50mg
dihydroartemisinin and350mgpiperaquinephosphate, is ﬁrst pro-
duced from Myanmar Pharmaceutical Factory (MPF) of Ministry of
Industry in 2009.
Methods: An hospital based clinical study following 28 days
WHO standard therapeutic efﬁcacy test was conducted at 1000
Bedded Hospital in Mingalardon, Yangon Division, 300 Bedded
Hospital in Myitkyinar, Kachin State and 100 Bedded Hospital in
Lashio, Shan State on a total of 23 patients with acute uncom-
plicated falciparum malaria between March to October 2010, to
study the effectiveness, tolerability and safety of piperamisinin. The
patients who met the inclusion criteria were given Piperamisinin
combined tablets with the dosage of 3 tablet at 0-Hr, 24-Hr & 48-
Hr. The patientswere thoroughly assessed andmonitored clinically
including ECG, parasitologically, haematologically, and biochemi-
cally (Blood sugar, urea & serum creatinine) for side effects during
the 28 days of conﬁnement at the respective hospitals.
Results: The participants were 29.52 years old on average and
ranged from 14 to 57 years of age. Initial parasitaemia was 1983.16
± 2685.45 per L whereas initial temperature was 37.8 ± 0.88
◦C. Fever clearance time (FCT) and parasite clearance time (PCT)
were 14.63 ± 10.72 hours 27.18 ± 11.44 hours respectively. Nei-
ther early treatment failurenor late treatment failurewasobserved.
Adequate clinical and parasitological response (ACPR) was 100
percents.There were no serious clinical or laboratory side effects
observed in the study.
Conclusion: In general, Domestically manufactured
Piperamisinin combined tablet is safe and effective for the
treatment of uncomplicated falciparum malaria patients in three
different states and divsion of Myanmar.
http://dx.doi.org/10.1016/j.ijid.2012.05.399
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Malaria and co-infection among traveller in a refferal hospital:
a case series
H. Habib1, S. Lardo2,∗
1 University of Indonesia, Jakarta, Indonesia
2 Gatot Subroto Central Army Hospital, Jakarta, Indonesia
Background:Areferral hospital in tropical regionoften received
referral malaria patient with many co infection undiagnosed and
haveno respon to the therapy fromthe local hospital. Becauseof the
indaquate therapy before, the referral patient usually have atypical
sign and symptoms.The epidemiology of infection from the region
where patient stay should take into consideration because patient
could have multiple infection.
Methods: Here we report a case series of three refferal patients
of Gatot Subroto Central ArmyHospital Jakarta, Indonesiawithmix
falciparum and vivax infection, falciparum and H1N1, vivax and
dengue.
Results:Case1wasamalepatientwith suddenonsetof continu-
oushighgrade fever for threedays.Hewasanarmyonduty referred
